Chiusura precedente | 25,29 |
Aperto | 24,27 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 24,27 - 25,29 |
Intervallo di 52 settimane | 24,27 - 25,29 |
Volume | |
Media Volume | N/D |
Capitalizzazione | 1,818B |
Beta (5 anni mensile) | 0,54 |
Rapporto PE (ttm) | 19,95 |
EPS (ttm) | 0,91 |
Prossima data utili | 27 lug 2022 - 01 ago 2022 |
Rendimento e dividendo (forward) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Positive results of preceding Phase 2 trial to be featured in oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting Figure 1 Figure 1 MENLO PARK, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, today announced that,
MENLO PARK, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2022. Financial Results Revenue of $93.7 million, compared to $79.4 million in first quarter 2021Reiterated 2022 revenue guidance
MENLO PARK, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 5, 2022. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to Join